SMN1

Chr 5

survival of motor neuron 1, telomeric

Also known as: BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3, SMA4, SMA@

This gene is part of a 500 kb inverted duplication on chromosome 5q13. This duplicated region contains at least four genes and repetitive elements which make it prone to rearrangements and deletions. The repetitiveness and complexity of the sequence have also caused difficulty in determining the organization of this genomic region. The telomeric and centromeric copies of this gene are nearly identical and encode the same protein. However, mutations in this gene, the telomeric copy, are associated with spinal muscular atrophy; mutations in the centromeric copy do not lead to disease. The centromeric copy may be a modifier of disease caused by mutation in the telomeric copy. The critical sequence difference between the two genes is a single nucleotide in exon 7, which is thought to be an exon splice enhancer. Note that the nine exons of both the telomeric and centromeric copies are designated historically as exon 1, 2a, 2b, and 3-8. It is thought that gene conversion events may involve the two genes, leading to varying copy numbers of each gene. The protein encoded by this gene localizes to both the cytoplasm and the nucleus. Within the nucleus, the protein localizes to subnuclear bodies called gems which are found near coiled bodies containing high concentrations of small ribonucleoproteins (snRNPs). This protein forms heteromeric complexes with proteins such as SIP1 and GEMIN4, and also interacts with several proteins known to be involved in the biogenesis of snRNPs, such as hnRNP U protein and the small nucleolar RNA binding protein. Multiple transcript variants encoding distinct isoforms have been described. [provided by RefSeq, Jul 2014]

GeneReviewsResearchGenerating clinical summary…
LOEUF 1.93
Clinical SummarySMN1
Population Constraint (gnomAD)
Low constraint (pLI 0.02) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
88 unique Pathogenic / Likely Pathogenic· 54 VUS of 178 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — SMN1
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.93LOEUF
pLI 0.016
Z-score -0.63
OE 1.61 (0.481.93)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
0.06Z-score
OE missense 0.94 (0.531.68)
7 obs / 7.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?1.61 (0.481.93)
00.351.4
Missense OE?0.94 (0.531.68)
00.61.4
Synonymous OE?1.72
01.21.6
LoF obs/exp: 2 / 1.2Missense obs/exp: 7 / 7.4Syn Z: -0.86

ClinVar Variant Classifications

178 submitted variants in ClinVar

Classification Summary

Pathogenic55
Likely Pathogenic33
VUS54
Likely Benign13
Benign12
Conflicting10
55
Pathogenic
33
Likely Pathogenic
54
VUS
13
Likely Benign
12
Benign
10
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
28
12
15
0
55
Likely Pathogenic
16
14
3
0
33
VUS
3
26
21
4
54
Likely Benign
0
0
10
3
13
Benign
0
0
11
1
12
Conflicting
10
Total4752608177

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

13 pathogenic / likely-pathogenic (of 68) ClinVar copy-number / structural variants overlap SMN1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

SMN1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Spinal Muscular AtrophySMA

UK SMA Patient Registry

RECRUITING
NCT04292574Newcastle UniversityStarted 2008-07-13
Patient Registry
Spinal AmyotrophyInfantile Spinal Muscular AtrophyJuvenile Spinal Muscular Atrophy

Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy

RECRUITING
NCT06562283Phase NACentre Hospitalier Universitaire de Saint EtienneStarted 2024-12-06
Thumb testGrip testQuadriceps Intermittent Fatigue test (QIF test))
Muscular Atrophy, Spinal

A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

NOT YET RECRUITING
NCT07444450Phase PHASE3BiogenStarted 2026-09-04
SalanersenSham Procedure
Spinal Muscular Atrophy

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

RECRUITING
NCT07444476Phase PHASE3BiogenStarted 2026-04-03
Salanersen
Spinal Muscular Atrophy (SMA)

Long Read Analysis in Spinal Muscular Atrophy - LOREASI

RECRUITING
NCT07332702Phase NAUniversity Hospital, RouenStarted 2025-05-15
blood sample
Spinal Muscular Atrophy (SMA)

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

RECRUITING
NCT04174157Novartis PharmaceuticalsStarted 2018-09-25
Prospective observational registryZolgensma
Spinal Muscular Atrophy (SMA)

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)

RECRUITING
NCT05747261Phase PHASE1, PHASE2BiocadStarted 2023-02-02
ANB-004, dose 1ANB-004, dose 2ANB-004, dose 3
Spinal Muscular AtrophySMASpinal Muscular Atrophy Type 2

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

RECRUITING
NCT07047144Phase PHASE2Scholar Rock, Inc.Started 2025-09-15
ApitegromabNusinersenRisdiplam
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, IncludingSickle Cell DiseaseCystic Fibrosis

Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders

RECRUITING
NCT06147414Assistance Publique - Hôpitaux de ParisStarted 2024-10-23
Blood sample
Muscular Atrophy, Spinal

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

RECRUITING
NCT07221669Phase PHASE3BiogenStarted 2026-04-28
Salanersen
Spinal Muscular Atrophy Type I

Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1

RECRUITING
NCT07070999Phase PHASE1, PHASE2Gemma BiotherapeuticsStarted 2026-01-06
GB221
Spinal Muscular Atrophy (SMA)

Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials

ACTIVE NOT RECRUITING
NCT05335876Phase PHASE3Novartis PharmaceuticalsStarted 2022-12-19
onasemnogene abeparvovec